Floatz logo

mk-2206

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

62 Active assets in the Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Inno-206
Falo, Louis, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →